Pharmaceutical Executive
Young & Partners crunches pharma's filings for, the first half of '08. The results? Ask the Japanese
M&As have become as essential as R&D to pharma's future, and this year is no exception. According to life-science investment bank Young & Partners (Y&P), 19 major deals have been inked so far, worth a total of $22.7 billion, indicating that 2008 is on track to match 2007's in volume (44 M&As), though not its dollar value ($79.5 billion).
Dollar Value of Worldwide Pharma Acquisitions
Only six deals have hit blockbuster status—the biggest by far Takeda's $8.8 billion grab of Millennium. In fact, '08 is shaping up as the year the Japanese drug industry makes its move into the global market. Five of the top 10 deals were made by Japanese firms, shoring up shop at home or placing stakes in the US.
For the rest of '08, Y&P predicts a slight drop-off in M&As, given a teetering global economy and the unknowns about healthcare policies with the Presidential election looming. Expect the year's volume to come in under the five-year average of $66.5 billion.
Dollar Value of Worldwide Biotechnology Acquisition
If cash-rich drug giants are unbothered by the financial climate, the same cannot be said for high-risk, low-revenue biotechs. While debt financing ($223 million) is on a par with last year's total ($363 million), equity has tanked, down from $5.8 billion in '07 to $1.1 billion, with only one IPO this year.
But biotech M&A action remains hot, as Big Pharma prowls for new drugs to plug holes in pipelines. With 10 deals adding up to $3.1 billion so far, '08 looks likely to match '07 in volume (21) and beat it in value ($4.3 billion). Yet none has hit the billion-dollar mark. According to Y&P, many of the mature biotechs were picked off in '06, when there were 25 deals totalling $9.8 billion.
Top 10 Deals-First Half 2008
Of course, the entire M&A story could be rewritten by a speedy meeting of minds between Roche and Genentech. That deal would boost the year's final tally by as much as $55 billion. But at that price, an agreement is not likely to come easy. —Walter Armstrong
Asembia 2025: Therapy Advancements Highlight Growing Cost and Access Concerns
April 30th 2025Fran Gregory, VP, emerging therapies, Cardinal Health, discusses the evolving cell and gene therapy landscape, highlighting pipeline growth, cost challenges, and emerging therapeutic areas beyond oncology and hematology.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
FDA Approves AbbVie’s Rinvoq as First Oral JAK Inhibitor for Giant Cell Arteritis
April 30th 2025AbbVie secures FDA approval for Rinvoq as the first oral Janus kinase inhibitor indicated for giant cell arteritis, expanding its immunology portfolio and signaling strategic growth opportunities in underserved autoimmune markets.